Skip to main content

Guideline Updates

NCCN Updates Clinical Practice Guideline for Bladder Cancer

March 24, 2021

On March 22, 2021, the National Comprehensive Cancer Network (NCCN) released an update to its clinical practice guideline for bladder cancer.

The version 2.2021 update featured a change to second-line systemic therapy for locally advanced or metastatic disease (Stage IV; post-platinum). Atezolizumab was removed as an alternative preferred regimen based on the voluntary withdrawal of the FDA indication.—Janelle Bradley

Back to Top